SPEXIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0618 CHF | -4.04% |
|
+4.75% | +50.73% |
| May. 01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.63M | - | - | - | - | - | |
| 89.87B | ||||||
| 37.57B | ||||||
| 32.75B | ||||||
| 26.47B | ||||||
| 14.25B |
- Stock Market
- Equities
- POLN Stock
- Charts Spexis AG
- Sector Chart
